SAN DIEGO, May 8, 2026
Actio Biosciences announced the initiation of the KYRON Phase 1b/2 clinical trial evaluating ABS-1230, an investigational precision therapy designed for the treatment of KCNT1-related epilepsy, a rare and frequently fatal pediatric developmental epileptic encephalopathy associated with severe treatment-resistant seizures and profound neurological impairment. The company also confirmed that ABS-1230 has been accepted into the U.S. FDA’s Rare Disease Evidence Principles (RDEP) process, a specialized regulatory framework intended to support the development of therapies targeting ultra-rare genetic disorders with major unmet medical need.
The dual milestone significantly strengthens Actio’s regulatory and clinical development pathway as the company advances a targeted therapy specifically engineered to inhibit the underlying disease-driving KCNT1 potassium ion channel dysfunction responsible for seizure activity in affected patients. KCNT1-related epilepsy remains one of the most devastating forms of childhood epilepsy, with many patients experiencing seizure onset during infancy alongside severe developmental delays, intellectual disability, motor impairment, and life-threatening complications despite treatment with existing anti-seizure medications.
KYRON Trial Evaluates Precision Therapy in Pediatric Patients
The KYRON Phase 1b/2 study will evaluate the safety, tolerability, pharmacokinetics, seizure activity reduction, and neurodevelopmental effects of ABS-1230 in children and young adults between one month and 21 years of age diagnosed with KCNT1-related epilepsy. The trial is structured into three components, beginning with a 12-week open-label single-arm treatment phase, followed by a 12-week randomized placebo-controlled study, and concluding with an optional long-term extension phase for participants completing earlier study stages. Actio stated that ABS-1230 can be administered orally or through feeding tubes, an important consideration for pediatric patients suffering from advanced neurological dysfunction and feeding complications.
Enrollment will initially focus on older children and young adults before expanding into infant populations after safety and dose evaluations are completed in each age group. The company emphasized that ABS-1230 was specifically designed as a potent and selective orally available small molecule KCNT1 inhibitor capable of directly targeting the genetic mechanism responsible for disease progression. In preclinical studies, the therapy demonstrated activity against all tested pathogenic KCNT1 mutations, supporting the possibility of broad applicability across genetically confirmed KCNT1-related epilepsy patients. Earlier Phase 1a healthy volunteer data also demonstrated that multiple dose levels of ABS-1230 were well tolerated with no serious adverse events reported, reinforcing confidence in the program’s safety profile entering pediatric clinical evaluation.
Advertisement
FDA Rare Disease Evidence Principles Process Supports Development Strategy
Actio’s acceptance into the FDA’s Rare Disease Evidence Principles process represents a major regulatory milestone for the ABS-1230 program. Established in 2025, the RDEP framework was specifically designed to facilitate development and potential approval pathways for therapies targeting ultra-rare diseases involving clearly defined genetic drivers and severe unmet medical need. Under this framework, FDA may consider alternative approaches for establishing substantial evidence of effectiveness, including reliance on smaller or single-arm clinical studies combined with strong confirmatory evidence.
The company stated that participation in the RDEP process may help accelerate regulatory alignment and improve the efficiency of clinical development for ABS-1230. In addition to RDEP acceptance, ABS-1230 has already received FDA Fast Track designation, Rare Pediatric Disease designation, and Orphan Drug designation, highlighting the urgency surrounding the need for effective treatments in KCNT1-related epilepsy. Company executives noted that the regulatory support reflects growing recognition of the devastating burden experienced by affected children and families who currently have extremely limited therapeutic options beyond conventional seizure management approaches.
Precision Neurology Pipeline Expands Rare Disease Focus
Actio Biosciences continues advancing a broader strategy centered on translating genetic discoveries into precision therapies for severe neurological disorders and rare diseases. Beyond ABS-1230, the company is developing additional clinical-stage programs targeting genetically defined conditions, including therapies for neuromuscular disorders and central nervous system diseases. Leadership at Actio emphasized that targeting the underlying molecular drivers of disease rather than merely managing symptoms represents a critical shift in neurological drug development.
The company believes precision-designed therapies such as ABS-1230 could potentially transform treatment paradigms for devastating pediatric epilepsies that currently lack effective long-term therapeutic solutions. The launch of the KYRON study positions Actio among a growing group of biotechnology companies leveraging genetic science, targeted ion channel modulation, and precision medicine approaches to address severe childhood neurological diseases with high mortality risk and limited treatment options.
Source: Actio Biosciences press release
